Evidence map›Paper›PMID 42859328›Full record

ArticleJournal of thrombosis and thrombolysis2026

Structural and functional disruption of fibrinogen by a novel FGG c.1099G > C (p.Ala367Pro) variant: an integrated in silico mechanistic study.

Wenbin Tuo, Ye Zeng, Wu Wang, Jun Wang, QinZhen Cai, Mo Wu, Yun Xiang, Jun Guo

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of thrombosis and thrombolysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wenbin Tuo *Department of Laboratory Medicine, Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430016, P.R. China.
Ye Zeng *Department of Laboratory Medicine, Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430016, P.R. China.
Wu Wang *Department of Critical Care Medicine, Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430016, P.R. China.
Jun WangDepartment of Laboratory Medicine, Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430016, P.R. China.
QinZhen CaiDepartment of Laboratory Medicine, Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430016, P.R. China.
Mo WuDepartment of Laboratory Medicine, Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430016, P.R. China.
Yun XiangDepartment of Laboratory Medicine, Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430016, P.R. China. xiangyun5272008@163.com.
Jun GuoDepartment of Critical Care Medicine, Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430016, P.R. China. Guo0205jun@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to elucidate the molecular pathogenesis of the novel FGG p.Ala367Pro variant, recently identified in a patient with congenital dysfibrinogenemia (CD), using an integrated in silico approach. A comprehensive computational pipeline was applied. Pathogenicity was evaluated using MutationTaster, PolyPhen-2, PROVEAN, and VarCards. Structural effects were modeled with AlphaFold3 and analyzed via PyMOL. Protein stability was assessed using Missense3D, DUET, MUpro, DynaMut2, and I-Mutant2.0. Evolutionary conservation was evaluated using ConSurf and Clustal X. The p.Ala367Pro variant was consistently predicted to be deleterious by all pathogenicity prediction tools. Structural modeling indicated that the alanine-to-proline substitution predicteda local alpha-helix and abolishes a key hydrogen bond, leading to significant destabilization of the γ-chain tertiary structure (consistently negative ΔΔG values across stability prediction tools). The Ala367 residue was found to be perfectly conserved across species. These findings support a potentially mechanistic that the FGG p.Ala367Pro mutation is a pathogenic variant that disrupts fibrinogen function by compromising γ-chain stability and structure. Our work establishes a in silico framework for the functional validation of novel fibrinogen variants, crucial for interpreting genetic findings and guiding clinical management in CD.

Indexed as

Congenital dysfibrinogenemia (CD)FGGIn-silico analysisMutation pathogenicityProtein structure

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.